ABOUT EVENT
The 4th iPSC Drug Development & Manufacturing Summit – What Was It About?
With new start-ups like Kenai Therapeutics emerging and a growing number of iPSC drug developers getting close to in-patient clinical trials, there is a clear need to unite the iPSC community to map out the evolving clinical and commercial landscape and overcome the shared engineering and scale up challenges in this rapidly advancing field.
The 4th iPSC Drug Development & Manufacturing Summit was an unparalleled premier event that united leading experts and stakeholders in this field to serve as a platform for sharing and discussing the latest innovations in the iPSC space – and for the first time in 4 years, we united R&D teams, manufacturing experts and business leaders, across 2 tracks of content for 3-days of cutting edge data presentations and strategic cross-functional discussions.
Don't miss this golden opportunity to shape the future of your iPSC development pipeline.
End-to-End iPSC Drug Development Content from Conception to Clinic
Top Reasons to Attend in 2025:
Discover the breakthrough work of Kenai Therapeutics, as they showcase innovative iPSC technologies to combat Parkinson’s disease following their latest funding round
Reinvigorate your preclinical pipeline with learnings from iPSC drug developers who are innovating in entirely new indications with presentations from Tome Biosciences and Thymmune
Gain insights into the future of iPSC manufacturing, as leaders from Aspen Neuroscience and the NIST discuss integrating AI and automation into their processes to improve product quality and cut costs
Optimize your iPSC differentiation protocols to improve your product’s efficacy with insights from Century Therapeutics and Stemson Therapeutics
Dive into our brand-new two-track structure to tailor your learning on the most pressing challenges whether they be preclinical research or manufacturing
TAKE A LOOK AT THE 2024 AGENDA TODAY!
Who Attended?
INQUIRE HERE TO LEARN MORE ABOUT THIS MUST-ATTEND EVENT!
What Your Peers Had to Say
"There was a strong presence and innovative portfolios of several leading players in the domain of CAR-T cell therapies"
Senior Scientist, Orizuru, Past Attendee